PKCζ Mediates Breakdown of Outer Blood-Retinal Barriers in Diabetic Retinopathy. by Omri, S. et al.
PKCf Mediates Breakdown of Outer Blood-Retinal
Barriers in Diabetic Retinopathy
Samy Omri1,2,3, Francine Behar-Cohen1,2,3,4, Pierre-Raphae¨l Rothschild1,2,3,4, Emmanuelle Ge´lize´1,2,3,4,
Laurent Jonet1,2,3, Jean Claude Jeanny1,2,3, Boubaker Omri1,2,3., Patricia Crisanti1,2,3*.
1 Institut National de la Sante´ et de la Recherche Me´dicale, U872, Paris, France, 2Universite´ Paris Descartes, UMRS 872, Paris, France, 3Centre de Recherche des Cordeliers,
UPMC-Paris6, UMRS 872, Paris, France, 4Hoˆtel-Dieu Hospital, AP-HP, Paris, France
Abstract
Aims/hypothesis: Diabetic macular edema represents the main cause of visual loss in diabetic retinopathy. Besides inner
blood retinal barrier breakdown, the role of the outer blood retinal barrier breakdown has been poorly analyzed. We
characterized the structural and molecular alterations of the outer blood retinal barrier during the time course of diabetes,
focusing on PKCf, a critical protein for tight junction assembly, known to be overactivated by hyperglycemia.
Methods: Studies were conducted on a type2 diabetes Goto-Kakizaki rat model. PKCf level and subcellular localization were
assessed by immunoblotting and immunohistochemistry. Cell death was detected by TUNEL assays. PKCf level on specific
layers was assessed by laser microdissection followed by Western blotting. The functional role of PKCf was then evaluated
in vivo, using intraocular administration of its specific inhibitor.
Results: PKCf was localized in tight junction protein complexes of the retinal pigment epithelium and in photoreceptors
inner segments. Strikingly, in outer segment PKCf staining was restricted to cone photoreceptors. Short-term
hyperglycemia induced activation and delocalization of PKCf from both retinal pigment epithelium junctions and cone
outer segment. Outer blood retinal barrier disruption and photoreceptor cone degeneration characterized long-term
hyperglycemia. In vivo, reduction of PKCf overactivation using a specific inhibitor, restored its tight-junction localization and
not only improved the outer blood retinal barrier, but also reduced photoreceptor cell-death.
Conclusions: In the retina, hyperglycemia induced overactivation of PKCf is associated with outer blood retinal barrier
breakdown and photoreceptor degeneration. In vivo, short-term inhibition of PKCf restores the outer barrier structure and
reduces photoreceptor cell death, identifying PKCf as a potential target for early and underestimated diabetes-induced
retinal pathology.
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Introduction
Diabetic retinopathy (DR) is one of the most severe complica-
tion of diabetes and the leading cause of visual loss among western
working-age adults [1,2]. Visual impairment results mostly from
macular edema (ME), defined as fluid accumulation in/or under
the macula, which is the specialized retinal area responsible for
visual acuity [3,4]. Retinal edema results from an imbalance
between fluid entry and fluid withdrawal, but the precise
mechanisms of ME are still elusive. Fluid entry is controlled by
the inner blood retinal barrier (BRB) made of TJ between the
endothelial cells of the retinal vasculature together with a complex
network of glial components. The retinal pigment epithelium
(RPE) is a monolayer of pigmented cells with tight-junctions that
control mostly fluid exit from the sub-retinal space through the
choroid. The apical side of RPE faces the photoreceptor outer
segments of the neuroretina, and the basolateral side lies on
Bruch’s membrane, which separates the RPE from the underlying
fenestrated endothelium of the choriocapillaris [5]. We have
recently evidenced that tight-like junctions containing occludin are
present also at the OLM, mainly between Mu¨ller glial cells and
cones, the only photoreceptors of the macula [6]. Among the
molecules involved in TJ formation and maintenance, the critical
role of the PAR6/PKCf/PAR3 scaffold complex in cell polarity
has been extensively studied [7–13]. Any protein loss of this
complex leads to mislocalization of the others [14]. PKCf also
phosphorylates occludin and thereby promotes assembly of TJ
[15] and it was shown that hyperglycemia modulates its
activity.[16,17]
Whilst extensive work has focused on hyperglycemia-induced
inner BRB breakdown, much less attention has been carried
towards the effect of hyperglycemia on the outer retina.
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The aim of our work was to evaluate in a model of type 2 non-
obese diabetic rat, the effects of hyperglycemia on the outer retinal
barriers components and their consequences on the retinal
structure. We observed that rupture of the outer retinal barriers
is an early hyperglycemia-induced event and that it is associated to
photoreceptor cell death. Moreover, we identified PKCf as a
potential regulatory target in these early events.
Materials and Methods
Animals
The animals used in this work were treated in accordance with
the Association for Research in Vision and Ophthalmology
(ARVO) statement. Experimental procedures were submitted
and approved by the local ethics committee of Paris Descartes
University.
Goto-Kakizaki (GK) rats (Taconic Europe, Denmark), a Wistar
non-obese model of Non-Insulin Dependent type 2 Diabetes were
studied at 6 and 12 months of age. Non-fasting blood glucose level
was measured using Accutrend GC and Accu-check compact
equipments (Roche). A plasma glucose level.250 mg/dl
(14 mmol/l) defined the diabetic status. In contrast to control
Wistar rats, GK rats develop hyperglycemia at around 14 weeks of
age and remain diabetic thereafter (Table 1). Controls were
selected from age-matched rats with plasma glucose levels
, 150 mg/dl (8.5 mmol/l).
Immunohistochemistry on flatmounted neuroretina or
RPE/choroid
After sacrifice, rat eyes were enucleated, fixed in 4% parafor-
maldehyde (PFA) for 15 min at room temperature and sectioned
at the limbus; the anterior segments were discarded. Neuroretinas
and RPE/choroids were dissected and fixed separately for an
additional 15 min in acetone at 220uC. Specimens were then
incubated overnight at 4uC with primary antibodies diluted in PBS
supplemented with 10% fetal calf serum (FCS) and 0.1% Triton
X-100. Primary antibodies used were: rabbit polyclonal anti-
occludin (71–1500) (Zymed, San Francisco, CA, USA) (dilution
1:200); mouse monoclonal anti-PKCf (ab57432) raised against
amino acid 165 to 255, specific of the N-terminal region of the
PKCf; rabbit polyclonal anti-Partitioning-defective protein 3
(PAR3) (ab64840) (Abcam, Cambridge, UK) (dilution 1:400);
anti-Partitioning-defective protein 6 (PAR6) (H-90) (sc-25525)
(dilution 1:400) and anti-b-tubulin (D-10) (sc-5274) (Santa Cruz
Biotechnology, Inc, Santa Cruz, CA, USA) (dilution 1:400); Goat
polyclonal Blue-sensitive opsin (SC 14363) (Santa Cruz Biotech-
nology, Inc, Santa Cruz, CA, USA) (dilution 1:200); rabbit
polyclonal anti- P-PKCf (sc-12894-R) raised against the phospho-
threonin 410 amino acid (p-T410) of the PKCf (dilution 1:400),
anti-P65-NF-kB (sc-33039-R) (serine 311-R), (Santa Cruz Bio-
technology, Inc, Santa Cruz, CA, USA) (dilution 1:200).
The corresponding Alexa secondary antibodies (Invitrogen life
technology Carlsbad) were used to reveal the primary antibodies
(dilution 1:250), and sections were counterstained with 49, 6-
diamino-2-phenylindol (DAPI) (Sigma Aldrich St. Louis, MO
USA) (dilution 1:5000).
Sections and flatmounts were viewed with a fluorescence
microscope (BX51; Olympus, Rungis, France) and confocal
microscope (LSM 510 laser scanning microscope Zeiss, Carl
Zeiss, Le Pecq, France). Images were then processed by Photoshop
software for preparation of the final images.
The immunostaining procedure was repeated at least 3 times to
seek for consistency of the positive results. Negative controls were
obtained by staining procedures that omitted the primary
antibody.
Laser microdissection of specific retina regions
The OLM region was extracted from the neuroretina by laser
microdissection of the outer retina on frozen sections using a Leica
AS LMD system (Leica, Solms, Germany) as previously described
by Burbach and colleagues [18]. Protein extracts from at least 30
sections of 40 mm per eye were used for immunoblot analysis.
Tunel assay
Cell apoptosis was assessed with a terminal dUTP nick-end
labeling (TUNEL) kit (Roche, Indianapolis, IN, USA)) on retina
sections. Staining conditions were as specified in the manufactur-
er’s instructions.
Western blotting
Protein extracts from RPE/choroid and from laser microdis-
sected OLM regions were obtained from diabetic rats of 6 and 12
month of age and from age-matched controls. Proteins were
homogenized in a lysis buffer (10 mM Tris-HCl, pH 7.5, 1 mM
EDTA, 1 mM EGTA, 150 mM NaCl, 0.5% Nonidet P40, 1%
Triton X-100, b-mercaptoethanol) containing a protease inhibitor
cocktail (Roche, France). Protein concentration was determined
using a Bradford assay. Proteins (40–50 mg) were subjected to
SDS-PAGE in a 12% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, and electroblotted onto nitrocellulose membranes
(Schleicher and Schuell BioScience, Dassel, Germany). Mem-
branes were then incubated with: mouse monoclonal anti-PKCf
(ab57432) raised against amino acid 165 to 255, specific of the N-
terminal region of the PKCf (Abcam, Cambridge, UK) (dilution
1:400); rabbit polyclonal anti PKCf–P (sc-12894-R) raised against
the phospho-threonine 410 amino acid (p-T410) of the PKCf
(dilution 1:400), anti-Partitioning-defective protein 6 (H-90) (sc-
25525) (dilution 1:200) and anti-b-tubulin (D-10) (sc-5274) (Santa
Cruz Biotechnology, Inc, Santa Cruz, CA, USA) (dilution 1:400).
Rabbit polyclonal anti-Partitioning-defective protein 3 (07-330)
(EMD Millipore Life Science division of Merck KGaA of
Darmstadt, Germany)(dilution 2 m/ml). Then, membranes were
Table 1. Characteristics of the study animals.
Control Diabetes
Age (months) 6 12 6 12
Number of animals 24 24 24 24
Weight (g 6 SEM) 212610 34167 305615 387615
Blood Glucose level (mmol/l 6 SEM) 6.3360.67 7.4460.28 19.3360.56a 22.3960.67a
a: diabetes versus controls, P value,0.05.
doi:10.1371/journal.pone.0081600.t001
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incubated with the corresponding peroxidase-conjugated F(ab)2
fragment (Caltag, Burlingame, Canada) (dilution1:4000) second-
ary antibodies. Immunoreactive bands were detected with the
ECL Western blotting Detection Reagents Kit (Thermo scientific
inc, IL, USA). The relative abundance of individual proteins
identified was quantified by scanning densitometry. For the
phosphorylated PKCf (PKCf -P) the relative band intensity was
calculated in comparison to the non phosphorylated PKCf after
densitometry analysis (Adobe photoshop software).
Intravitreal injection of a specific PKCf inhibitor
Rats of 6 months of age were anesthetized with an intraper-
itoneal injection of pentobarbital (40 mg/kg Nembutal, Abbot,
Saint-Remy sur Avre, France). Pupils were dilated with the
instillation of a 1 drop of 5% tropicamide (Ciba Vision, Toulouse,
France), and locally anesthetized with a 1 drop of 1% tetracaı¨ne
(Ciba Vision, Toulouse, France). Injections, into the vitreous of a
3 ml sterile pyrogen-free saline containing either a PKCf specific
inhibitory peptide (n = 5) (myr-DIYRRGARRWRKL, ref. 539624
Lot B42131, Calbiochem) or a sham (n = 5), were performed as
previously described [19–21] through sterile syringes with a 30–
gauge needle (Microfine: Becton Dickinson, Meylan, France). The
injection procedure was monitored under a surgical microscope.
Semithin sections
Eyes were fixed for 1 hour in 2.5% glutaraldehyde in cacodylate
buffer (0.1 mol/L, pH 7.4). Eyes were dissected, fixed for 3 hours,
postfixed in 1% osmium tetroxide in cacodylate buffer, and
dehydrated in graduated ethanol solutions. Samples were included
in epoxy resin and oriented. Semithin sections (1 mm), ultra
microtome Reichert Ultracut E [Leica], were stained by toluidine
blue.
Fluorescence quantification
Fluorescent images were scanned at the same magnification and
exposure conditions. Quantification was performed using the
Image J software (National Institutes of Health, Bethseda, MD,
USA). First, the total area of the section was measured, and PKCf
specific areas were determined. The percentage of PKCf was then
determined.
Statistics
For continuous variables, the mean 6 SEM were provided.
Comparisons were performed by the non parametric, Mann–
Whitney test (Prism software version 4.0c; GraphPad Software,
San Diego, CA). Statistical significance was accepted for P value
,0.05.
Results
Hyperglycemia-induced changes in PKCf activity and
distribution in RPE cells is associated with barrier
integrity alteration
PKCf level was evaluated by Western blotting on RPE/choroid
protein extracts and its cellular localization was analyzed by
immunohistochemistry on RPE/choroid flat mounts. Two PKCf
antibodies were used: - one directed against the N-terminal (N-ter)
domain, - the other against the activated form of PKCf,
phosphorylated at the Thr 410 residue (p-T410).
Total PKCf levels did not differ significantly in diabetic RPE as
compared to the control non-diabetic rats of 6 and 12 months of
age (Fig 1), but in diabetic rats, its phosphorylated (p-T410) active
form increased (by around 40%) at 6 months of age and then
significantly decreased (by around 60%) at 12 months of age
(Fig 1). There is therefore a biphasic activation state of PKCf in
the time course of diabetic retinopathy.
Immunolocalization of total PKCf in RPE cells of control rats
was found to be highly organized and appeared as focal spots
within the loops depicted by occludin protrusions from both sides
of the continuous occludin labeling found at the cell–cell contacts
(Fig 2a). Conversely, in RPE cells from 6-month-old diabetic rats,
the PKCf staining was either barely or not detectable associated to
the TJ but instead a diffuse staining of PKCf was observed in the
cytoplasma (Fig 2b). At this stage, the outer BRB did not seem to
be significantly disrupted. At 12 months of age, in diabetic RPE,
PKCf and occludin could be observed in the nuclei of cells, while
marked disruptions of the tight junctions with buttonhole
formation could be observed (Fig 2c). At this time point (12
months), to better localize the phosphorylated active PKCf form
as compared to the total PKCf, we used two distinct antibodies.
This allowed identify the phosphorylated form (PKCf-P) evenly
associated to the junction at the membrane in control RPE (Fig 2f).
In RPE from diabetic rats, the phosphorylated form seemed
reduced and weekly associated to the membrane, its distribution
pattern was also markedly discontinued and RPE intercellular
junctions exhibited various degrees of disruption (Figure 2g). To
better illustrate this change, we quantified the PKCf at the TJ/
total amount of PKCf ratio, showing indeed a significant
reduction in diabetic rats (Fig 2d). However, a diffuse labeling of
PKCf (Fig 2g) well correlated with the stable levels of total PKCf
during the time course of diabetes (as shown above in Figure 1).
Figure 1. Diabetes stage-specific retinal pigment epithelium
(RPE) level of PKCf and its activated phosphorylated form
PKCf-P T410. No significant changes were observed for PKCf level at
any stage between control and diabetic conditions. To the contrary,
PKCf-P T410 immunoreactivity was significantly (*P,0.05, Mann–
Whitney test) increased (by around 40%) at 6 months and then
decreased (by around 60%) at 12 months of diabetes compared to
controls.
doi:10.1371/journal.pone.0081600.g001
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Furthermore, we found that occludin was also delocalized from
the membrane further contributing to RPE TJ disruption (Fig 2e
and 2c). Of importance, we confirmed that PKCf localization
pattern in non-diabetic, non human primates flatmount RPE cells
was similar to that found in control rats (data not shown).
Hyperglycemia-induced BRB TJ disruption through
destabilization of the PAR3/PAR6 PKCf-associated
complex
Because both PAR3 and PAR6 proteins are known to interact
with PKCf at the tight junction protein complexes, PAR3 and
PAR 6 localization was investigated by immunohistochemistry and
quantified by Western blotting. Compared to controls, the 12-
month-old diabetic rat RPE cells, showed decreased immuno-
staining of both PAR3 and PAR6 at the tight junction structures
(Fig 3a). Furthermore, in RPE cells from 12-month-old diabetic
rats, both PAR3 and PAR6 protein levels were also significantly
decreased (Fig 3b).
Altogether, these results suggest that after 12 months of diabetes
duration, PKCf down regulation contributes to an imbalance of
the TJ protein complex composition and/or distribution that may
initiate RPE junction destabilization.
Beneficial effect of intravitreal injection of a PKCf
inhibitor on diabetic RPE barrier
The above described results suggest that PKCf overactivation
plays a role in the disruption of TJ in RPE during diabetes. To
ascertain this hypothesis, both control and diabetic rats at 6
months of age were given a single intravitreal injection of a PKC
inhibitor (IZ). Rats were then sacrificed and processed within
48 hours. In diabetic treated eyes (IZ), immunostaining on
flatmounted RPE showed restoration of PKCf organization
within the occludin loops, similar to what is observed in control
(CTL) animals (Fig 4a). Diabetic sham treated eyes (DIA)
exhibited either faint or no PKCf staining at the junction
(Fig 4a). Similarly, occludin staining was altered in 6-month-old
sham treated diabetic rats (DIA) and was restored by the treatment
Figure 2. Immunolocalization of PKCf and occludin in retinal pigment epithelium (RPE) flatmounts. In 6-month-old controls, PKCf
staining (red) appeared as focal spots within the loops depicted by occludin (green) protrusions (a). In age-matched diabetic conditions, no PKCf
labeling (box and green arrow) was observed (b). After 12 month of diabetes marked disruption of intercellular junctions (arrows) was evidenced (c).
At this stage the PKCf at the junctions (TJ)/total amount of PKCf ratio was significantly decreased for diabetic conditions (Image J software, National
Institutes of Health, Bethesda, MD) (d) and occludin internalization from the cell membrane into the cytoplasm was found (e). The colocalization of
PKCf (red) and PKCf-P (green) found in 12-month-old controls (f) was not present in age-matched diabetics (g). Furthermore the activated PKCf-P
form exhibited a discontinuous staining along the cell membrane (g).
doi:10.1371/journal.pone.0081600.g002
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(DIA+IZ) (Fig 4b). To note, controls treated by the PKCf inhibitor
(CTL+IZ) showed a marked decrease in the recruitment of
occludin at the membrane thereby confirming the role of this
kinase in TJ maintenance in normal conditions (Fig 4b).
Diabetes induces retinal morphological changes and
cone photoreceptor degeneration
Because PKCf is also tightly associated with junctions at the
outer limiting membrane and contributes to its integrity, we first
evaluated potential structural changes associated with diabetes in
Figure 3. Diabetes destabilizes and down regulates PAR3/PAR6 PKCf-associated protein complex. a) Upper panels: In 12-month-old
diabetic rats (DIA) PAR6 distribution in flatmount RPE showed a clear cytoplasmic relocation of PAR6 compared to age-matched control rats (CTL)
where PAR6 appeared as relative regular punctiform staining at the TJ levels. The same applied to PAR3 staining distribution (Lower panels). b) PAR6
and PAR3 immunoblotting on RPE cell extracts from 12-month-old rats showed a significant decrease of both protein levels in diabetic conditions
(statistical analysis was performed on the PAR3 180 KDa isoform).
doi:10.1371/journal.pone.0081600.g003
Figure 4. PKCf inhibition in 6-month-old diabetic rats restores PKCf localization and RPE junction structure. After a single intravitreal
injection, PKCf staining (red) was restored and relocated at the tight junctions (DIA+IZ) in RPE flatmounts (a). Diabetic treated rats (DIA+IZ) exhibited
relocalization of occludin staining at the membrane level and restoration of the intercellular junctions (b). Of importance PKCf inhibition in controls
induced marked alteration of occludin staining at the membrane, thereby confirming the critical role of this kinase in TJ formation and maintenance
in normal conditions (b).
doi:10.1371/journal.pone.0081600.g004
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the outer retina. In 12-month-old diabetic rats, the outer retina
appeared swollen (Fig 5a) with increased spaces between nuclei of
photoreceptors (Fig 5b, white arrow). The outer segments of
photoreceptors seemed also disorganized (Fig 5b) and cone cell
density measurement by peanut agglutinin labeling, a specific
marker of cone extracellular matrix, evidenced a 20% net loss of
cone photoreceptors in diabetic retinas as compared to controls.
(Fig 5c and 5d).
Diabetes reduces PKCf distribution in cone outer
segments and at the outer limiting membrane together
with structure integrity alterations in the outer
neuroretina
The outer limiting membrane (OLM) is constituted by tight
junctions between retinal Mu¨ller glial cells and photoreceptors.
Occludin along with PKCf, are hallmark proteins of TJ. In control
retina, we observed indeed that PKCf was expressed at the OLM
but it was also expressed in the inner segments of photoreceptors
and in inner and outer segments of cone photoreceptors, as
indicated with PNA staining of cones co labeled with PKCf
(Fig 6a). Thus outer segments of photoreceptors stained with
PKCf were only of the cone type as shown by the PNA staining
(Fig 6a). In diabetic rats, as early as 6 months of age, the cone
outer segment PKCf staining was lost (Fig 6a). We focused our
investigations on the S-cone photoreceptor subset (or blue
sensitive/short-wavelength cones) that have been reported to be
the most susceptible to degeneration during diabetic retinopathy in
humans [22–24]. The PKCf/blue opsin OS co-staining found on
retinal sections of 6-month-old control rats was lost in diabetic
conditions (Fig 6b). Furthermore a significant disruption of some
S-cone OS was observed suggesting early photoreceptor degener-
ation (Fig 6b).
At 12 months of diabetes, in addition to the changes observed at
6 months, discontinuities are observed at the OLM (Figure 6 c,
arrows). To further assess TJ disruptions at the OLM level we
performed a PKCf/occludin co-staining on flatmounted retina
from 12-months-old rats. We confirmed that the highly organized
honeycomb pattern of the OLM TJ found around photoreceptor
inner segments were markedly disrupted in diabetic rats (Fig 6d,
white arrows). Indeed, we evidenced a loss of OLM integrity with
reduced PKCf/occludin co-staining in diabetic rats.
PKCf specific inhibitor partially restores photoreceptor
alteration
To ascertain whether PKCf overactivation was associated with
its delocalization from cone outer segments in diabetic retinas we
performed intravitreal injections of a PKCf inhibitor in 6-month-
old diabetic rats and in age-matched controls. After 48 hours, rats
were sacrificed and processed.
Using two antibodies directed against PKCf and its activated
counterpart, the PKCf-P, we could observe as for RPE cells, that
at 6 months of diabetes (DIA), the active PKCf-P form is increased
and located in the inner segment of photoreceptor cells.
Furthermore, PKCf was delocalized from the cone OS to cone
IS (Fig 7a). Whilst the total levels of PKCf may not have changed,
its distribution and phosphorylation was significantly modified in
diabetic conditions.
Figure 5. Diabetes induces outer retinal edema and loss of cones photoreceptors. Diabetic retina (DIA) demonstrated increased
extracellular spaces within the outer nuclear layer (ONL) and photoreceptor segment disorganization, consistent with an edematous aspect of the
outer retina (Historesin (a) and semithin sections (b)). Peanut agglutinin labeling, a specific marker of cone extracellular matrix, evidenced a marked
decreased in cell cone density (c). Whole retina quantification of cones evaluated the net loss to be around 20% (d) as compared to controls
(p = 0.002, Mann–Whitney test).
doi:10.1371/journal.pone.0081600.g005
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Figure 6. Alteration of PKCf distribution in the outer retina is associated with cone outer segment and OLM disruption in diabetic
rats. PKCf staining was located in inner segments (IS) of rod and cones and exclusively in cone OS as evidenced by PKCf-PNA double labeling in 6-
month-old control rats (a). In 6-month-old diabetic rats, no OS staining was detected (a). Furthermore PKCf staining (red) was lost in S-cones,
specifically marked by Blue opsin staining (green), as compared to controls. Some S-cone OS also showed marked structural alterations, suggesting
early photoreceptor degeneration (b). In 12-month-old diabetic rats OLM discontinuity (arrows) was evidenced (c). OLM tight-junction disruption was
further confirmed on retinal flatmounts by an occludin/PKCf double staining (d, white arrows).
doi:10.1371/journal.pone.0081600.g006
Figure 7. In-vivo PKCf inhibition in 6-month-old-diabetic rats partially restores PKCf staining pattern in cone outer segments. The
phosphorylated active form PKCf-P (green) was found in IS of both control (CTL) and diabetic (DIA) rats (a). Diabetic inhibitor (DIA+IZ) treated rats
showed partial restoration of OS PKCf (red) staining (a). We performed laser micro dissection of the photoreceptor layer on cryosections (b) to study
layer-specific protein level by Western blotting analysis. The PKCf-P immunoreactivity increase found in diabetic rats (DIA) was partially restored in
treated rats (DIA+IZ).
doi:10.1371/journal.pone.0081600.g007
PKCf Role in Diabetic Outer Blood Retinal Barrier
PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e81600
Layer-specific protein level analysis, using a laser microdissec-
tion technique (Fig 7b) showed a stable protein level for PKCf but
a marked increase (by around 30%) of its activated form (Fig 7c) in
diabetic conditions (DIA). These findings are consistent with a
delocalization of PKCf from the cone outer segments to the inner
segments and an increase of its phosphorylated form in IS.
Intravitreal injection of a PKCf inhibitor (DIA+IZ) restored,
though partially, PKCf immunolocalization in cone outer
segments (Fig 7a) and PKCf activation level (Fig 7c).
Diabetes induces cone photoreceptor degeneration
through NF-kB pathway
Hyperglycemia and subsequent oxidative stress and/or inflam-
mation have been well documented in DR [25]. Besides PKCf
activation, these processes also involve NF-kB activation. More-
over PKCf is required for NF-kB-mediated cell death by a specific
phosphorylation at Ser 311 of its P65 subunit (P65-P) that finally
results in both a nuclear translocation and activation of NF-kB.
We therefore studied the implication of this pathway in
photoreceptor degeneration in our model. These studies were
performed on retinal cryosections from 6-month-old rats taking
advantage of a specific antibody directed against this serine 311
residue. TUNEL assay was performed to asses photoreceptor cell-
death.
A marked nuclear NF-kB P65-P subunit staining was detected
in diabetic retinas (DIA, white arrows) as compared to controls
(CTL) (Fig 8a). Strikingly this nuclear staining was selectively
observed in cones as shown by the double labeling P65-P and
PNA, a selective marker of cone extra cellular matrix. Further-
more, after PKCf inhibitor treatment (DIA+IZ), no P65-P staining
was observed in the outer nuclear layer (Fig8a).
TUNEL assay experiments performed at this disease-stage,
showed rare (about 4% of photoreceptors) but reproducible
TUNEL staining within some nuclei of the outer nuclear layer
(ONL) of diabetic retinas (Fig 8b, white arrows) consistent with
photoreceptor cell death through apoptosis. No significant positive
TUNEL staining was observed either in control retinas or in
diabetic treated retinas (data not shown). The scarce positive
TUNEL staining found in cells undergoing death through
apoptosis, could be explained by well-known short-lived nuclei
TUNEL-positive status.
Discussion
Retinal microvascular alterations and inner blood retinal barrier
breakdown have been the focus of most of the research conducted
so far in the field of diabetic retinopathy. Although a growing body
of evidence suggest a role for the outer retinal barrier in DR, the
literature deciphering the mechanism from a basic standpoint are
still limited [5,26,27]. Herein we address the implication of the
overlooked outer barriers in diabetic retinopathy in a rat model of
type2 diabetes. We have recently shown that the OLM is not only
formed by adherent junctions between glial Mu¨ller cells and
photoreceptors but also contains heterotypic tight-junctions,
suggesting that the OLM should be considered as part of the
outer retinal barrier [6]. However, what regulates this barrier and
Figure 8. PKCf specifically regulates NF-kB signaling pathway which participates to diabetes-induced cone photoreceptor
degeneration. In 6-month-old rat cryosections, the p65-P subunit of NF-kB (red) was only detected in diabetic (DIA) conditions in some nuclei of the
outer nuclear layer (arrows) and not in controls (CTL) or treated rats (DIA+IZ). The triple staining with addition of PNA (green), a specific cone marker,
confirmed that the nuclear translocation p65-P subunit of NF-kB exclusively occurred in cones (a). In age-matched rat cryosections, TUNEL assay
confirmed apoptosis of photoreceptors in diabetic (DIA) conditions (b).
doi:10.1371/journal.pone.0081600.g008
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what are the consequences of OLM barrier function alteration in
the course of diabetes has not been explored.
Among the tight-junction protein complex, essential for barrier
formation and maintenance, the critical role of PAR6/PKCf/
PAR3 scaffold has been extensively studied in different systems.
The loss of any of these proteins leads to mislocalization of the
others [18]. But, beyond its interaction with PAR3 and PAR6,
PKCf also phosphorylates occludin and thereby promotes tight-
junction assembly, identifying PKCf as a key player in the
regulation of tight-junction function integrity [15].
In the retina of diabetic rats, much before any microvascular
changes, we found that hyperglycemia induced PKCf over-
activation and dramatic localization changes of the protein that
preceded outer BRB alteration and photoreceptor degeneration.
PKCf immunostaining in inner segments of both cone and rod
photoreceptors was consistent with previous reports.[28,29]
However, we also observed that PKCf labeling restricted to cone
photoreceptors outer segments, was lost by short-term diabetes
and associated to alteration of cone structure. Long-term diabetes
was associated with photoreceptor degeneration involving NF-KB
activation. We have therefore identified PKCf as a potential
specific and early regulator of cone survival in the diabetic retina
offering a unique opportunity to use specific inhibitors to prevent
such alterations. In fact in vivo PKCf inhibition was sufficient in
our model to restore short-term hyperglycemia induced PKCf
alterations. We assume that outer BRB and photoreceptor
degeneration could thereby be prevented in the long-term by
such treatment. Obviously, further studies are required to confirm
its benefit over the long term.
These results are in agreement with in vitro endothelial cell
studies previously published demonstrating that TNF-a signals,
through PKCf/NF-k B pathway alter tight junction complexes
and increase retinal endothelial cell permeability [30]. Titchenell
et al. showed that PKCf inhibitor prevent vascular endothelial
growth factor (VEGF) induced blood retinal barrier dysfunction
[31]. Similar findings were recently reported in the brain where
PKCf activity mediated hypoxia-induced increase in cortical
blood-brain barrier permeability [32].
Several pathways can explain the biphasic activation of PKCf
during diabetes observed in the present study. The ceramide
pathway has been shown to be activated in type 2 diabetes patients
and their concentration is correlated to the severity of insulin
resistance [33]. Moreover it is now well established that while low
levels of ceramides activate PKCf, higher concentrations are on
the contrary responsible for its down activation [34,35]. Further-
more ceramide has been reported to stimulate phospholipase A2
thereby generating arachidonate, one of the first mediators of the
inflammatory cascade that can in turn promote or inhibit PKCf
activity depending on its concentration. [36–38]. Accumulating
evidence stemming from animal and human studies suggest a key
role for chronic low-grade inflammation in the development of
DR. In this context we have recently shown that PKCf inhibitor
treatment could also prevent the activation of microglial cells
within the retina thereby attenuating their proinflamamtory effect
supposed to participate substantially in photoreceptor cell death
[39].
In conclusion, we have identified PKCf activity as a potential
regulatory target in the early events taking place in the diabetic
retina: rupture of the outer limiting barrier and photoreceptor cell
death. This window of intervention, before any sign of microan-
giopathy could prevent irreversible vision loss in the time course of
diabetic retinopathy.
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